In addition, studies on OSCC (Zhang C. et al., 2019), prostatic carcinoma (Liu et al., 2019; Li W. et al., 2020), ESCC (Zong et al., 2019), glioma (Cheng Z. et al., 2020), and GBM (Wang et al., 2017) indicated that LEF1-AS1 can promote tumor formation in vivo. Here, LEF1 is linked to prostate carcinoma.